Literature DB >> 34981469

Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells.

Parisa Ziasarabi1, Amirhossein Sahebkar2,3,4, Faezeh Ghasemi5.   

Abstract

INTRODUCTION: Breast cancer is one of the main challenging areas in cancer treatment. Natural compounds such as curcumin and berberine have been approved with anticancer effects and are more favorable to people. Here, we investigated the potential synergistic anticancer effects of these two compounds in combination with the standard cancer drug 5-FU on the growth of MCF-7 breast cancer cells.
MATERIALS AND METHODS: This study tested the effects of six different treatments on cancer cell growth: A) control; B) curcumin; C) berberine; D) 5-FU; E) curcumin + berberine; and F) curcumin + berberine + 5-FU. The IC50 concentration of each treatment on cancer cell growth was determined using the MTT assay. Invasiveness of cells grown in 3D culture was analyzed using the transwell chamber technique. Expression levels of genes involved in cancer cell growth and survival (WNT1, APC, AXIN1, CTNNB1, TCF, MTOR, AKT1, MAPK1, PTEN, BIRC5, CCNG1) were evaluated by real-time PCR.
RESULTS: There was a reduction in cancer cell growth and invasion, and an increase in cellular decomposition across all treatment groups compared to the control with the strongest effects seen in the combined curcumin/berberine/5-FU group. The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.
CONCLUSIONS: All treatment groups had anti-growth, anti-invasion, and pro-apoptotic effects on MCF-7 breast cancer cells in culture. In addition, all treatment groups showed changes in the expression of the genes involved in cancer cell growth and survival with the strongest effects found for the curcumin/berberine/5-FU combination. Therefore, curcumin and berberine may improve the anticancer effects of chemotherapy and these natural compounds should undergo further testing as potential adjuvants.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  5-FU; Berberine; Breast cancer; Curcumin; MCF-7 cells; Nano-curcumin

Mesh:

Substances:

Year:  2021        PMID: 34981469     DOI: 10.1007/978-3-030-73234-9_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  31 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Cyclin D1 in breast cancer pathogenesis.

Authors:  Andrew Arnold; Alexandros Papanikolaou
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

Review 3.  Natural compounds for cancer treatment and prevention.

Authors:  Stefania Nobili; Donatella Lippi; Ewa Witort; Martino Donnini; Letizia Bausi; Enrico Mini; Sergio Capaccioli
Journal:  Pharmacol Res       Date:  2009-02-07       Impact factor: 7.658

4.  Recent Advances of Curcumin and its Analogues in Breast Cancer Prevention and Treatment.

Authors:  Charlotta D Mock; Brian C Jordan; Chelliah Selvam
Journal:  RSC Adv       Date:  2015-09-02       Impact factor: 3.361

5.  Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Authors:  Mayu Yunokawa; Fumiaki Koizumi; Yuka Kitamura; Yasufumi Katanasaka; Naoko Okamoto; Makoto Kodaira; Kan Yonemori; Chikako Shimizu; Masashi Ando; Kenkichi Masutomi; Teruhiko Yoshida; Yasuhiro Fujiwara; Kenji Tamura
Journal:  Cancer Sci       Date:  2012-08-01       Impact factor: 6.716

Review 6.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

Review 7.  The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

Authors:  Taj D King; Mark J Suto; Yonghe Li
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

Review 8.  A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs.

Authors:  Yiyi Sun; Keli Xun; Yitao Wang; Xiuping Chen
Journal:  Anticancer Drugs       Date:  2009-10       Impact factor: 2.248

9.  Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype.

Authors:  Gyu-Beom Jang; Ji-Young Kim; Sung-Dae Cho; Ki-Soo Park; Ji-Youn Jung; Hwa-Yong Lee; In-Sun Hong; Jeong-Seok Nam
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

Review 10.  Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.

Authors:  Xue-Qing Hu; Yang Sun; Eric Lau; Ming Zhao; Shi-Bing Su
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

View more
  2 in total

Review 1.  The Synergistic Effects of Curcumin and Chemotherapeutic Drugs in Inhibiting Metastatic, Invasive and Proliferative Pathways.

Authors:  Maria Younes; Rita Mardirossian; Liza Rizk; Tia Fazlian; Jean Paul Khairallah; Christopher Sleiman; Hassan Y Naim; Sandra Rizk
Journal:  Plants (Basel)       Date:  2022-08-17

Review 2.  Berberine as a potential agent for breast cancer therapy.

Authors:  Xiao-Dan Zhong; Li-Juan Chen; Xin-Yang Xu; Yan-Jun Liu; Fan Tao; Ming-Hui Zhu; Chang-Yun Li; Dan Zhao; Guan-Jun Yang; Jiong Chen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.